Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo Nordics ApS c/o

Our Cardiovascular Commitment

“We strive to help patients with cardiovascular diseases by developing innovative treatments. Since 2002 our cardiovascular treatments have improved outcomes of over 40 million* patients across Europe.”

We are the pioneer behind leading pharmaceuticals such as

  • Adrenalin (an adrenal cortex hormone agent that became the first blockbuster medicine of the 20th century) 
  • Pravastatin (a globally groundbreaking anti-hyperlipidemic agent)

Our current cardiovascular portfolio includes products for

  • Atrial fibrillation
  • Hypertension
  • Thrombotic disorders


*40 million patients treated with olmesartan and its combinations, prasugrel, edoxaban, pravastatin in selected countries